MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Illumina Interest Expense 2011-2026 | ILMN
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Illumina
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -292 M | -29 M | 61 M | 49 M | - | 52 M | 57 M | 37 M | 43 M | - | 41.7 M | 39.7 M | 37.8 M | 24.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 61 M | -292 M | 10.1 M |
Quarterly Interest Expense Illumina
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 M | 107 M | 4 M | -332 M | 18 M | 1 M | 20 M | - | - | 6 M | 6 M | - | 14 M | 16 M | 19 M | - | 11 M | 11 M | 11 M | - | 11 M | 15 M | 15 M | - | 15 M | 11 M | 11 M | - | 10 M | 8 M | 8 M | - | 9 M | 8 M | 8 M | - | 12.8 M | 11.2 M | 11.2 M | - | 11 M | 9.92 M | 9.74 M | - | 9.95 M | 10 M | 9.75 M | - | 9.48 M | 9.51 M | 9.2 M | - | 8.8 M | 9.42 M | 7.39 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 107 M | -332 M | 4.75 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B |  USA |
 |
Fulgent Genetics
FLGT
|
153 K | $ 18.53 | 1.59 % | $ 570 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 128.89 | -3.25 % | $ 16.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 137.76 | 0.7 % | $ 10.8 B |  Irlanda |
 |
Agilent Technologies
A
|
81 M | $ 137.36 | 1.46 % | $ 41.8 B | USA |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.7 | -5.56 % | $ 7.52 M | USA |
 |
Celcuity
CELC
|
5.33 M | $ 132.9 | 1.52 % | $ 6.21 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
106 K | $ 8.52 | -23.86 % | $ 11.3 M | USA |
 |
Castle Biosciences
CSTL
|
144 K | $ 21.21 | -4.07 % | $ 615 M | USA |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-595 K | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 22.88 | 0.79 % | $ 1.22 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 99.99 | 0.37 % | $ 6.75 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
17.6 K | - | - | $ 7.1 B |  Australia |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 178.15 | 1.13 % | $ 24.3 B |  Schweiz |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 10.59 | 3.88 % | $ 1.36 B | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 19.8 | 0.71 % | $ 443 M | USA |
 |
Natera
NTRA
|
9.32 M | $ 221.23 | 3.41 % | $ 21.8 B | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 184.01 | 1.47 % | $ 9.12 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 452.2 | 0.91 % | $ 13 B | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.01 | -5.09 % | $ 371 M | USA |
 |
Personalis
PSNL
|
205 K | $ 11.43 | 4.1 % | $ 1.02 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 26.53 | 0.28 % | $ 25.2 B |  Niderland |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.74 | 0.3 % | $ 281 M | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
2.58 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
367 | $ 2.39 | -1.74 % | $ 5.49 M | USA |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 68.81 | -0.32 % | $ 4.12 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 262.23 | 0.08 % | $ 21.8 B | USA |
 |
Thermo Fisher Scientific
TMO
|
-12 M | $ 496.35 | 1.87 % | $ 187 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.71 | 1.24 % | $ 255 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.18 | -1.34 % | $ 1.99 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 195.62 | -0.3 % | $ 21.7 B | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |